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Burrowing through the 
Heterogeneity: Review of Mouse 
Models of PTCL-nOS
Christine E. Cutucache* and Tyler A. Herek
University of Nebraska at Omaha, Omaha, NE, USA
Currently, there are 19 different peripheral T-cell lymphoma (PTCL) entities recognized 
by the World Health Organization; however, ~70% of PTCL diagnoses fall within one of 
three subtypes [i.e., peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), 
anaplastic large-cell lymphoma, and angioimmunoblastic T-cell lymphoma]. PTCL-NOS 
is a grouping of extra-thymic neoplasms that represent a challenging and heteroge-
neous subset of non-Hodgkin’s lymphomas. Research into peripheral T-cell lymphomas 
has been cumbersome as the lack of defining cytogenetic, histological, and molecular 
features has stymied diagnosis and treatment of these diseases. Similarly, the lacks of 
genetically manipulated murine models that faithfully recapitulate disease characteristics 
were absent prior to the turn of the century. Herein, we review the literature concerning 
existing mouse models for PTLC-NOS, while paying particular attention to the etiology 
of this heterogeneous disease.
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MURine MODeLS ReCAPiTULATinG CLiniCAL DiSeASe 
PReSenTATiOn OF MATURe T-CeLL LYMPHOMAS: PTCL-nOS
T-cell malignancies can largely be classified into those affecting precursor T-cells and those affecting 
mature, post-thymic T-cells. Peripheral T-cell lymphomas (PTCLs) fall into the latter category and 
it is postulated that the cell of origin is an activated, memory cell – most likely a CD44+ T cell. 
Importantly, these are potentially cells with self-renewal capacity – a capacity typically only seen in 
stem cells, such as hematopoietic stem cells (1–6). There exists some overlap in terms of characteris-
tics of PTCL-NOS and other T-cell lymphomas. For example, PTCL-NOS and angioimmunoblastic 
T-cell lymphoma (AITL) bear some similarities in terms of disease presentation, but PTCL-NOS is 
distinct from AITL in that AITL cells have solely a follicular T-helper phenotype (PD-1+, CXCL13+) 
and PTCL-NOS can include T-cells from differing subtypes (7). PTCLs express monoclonal T-cell 
receptor (TCR) or immunoglobulin rearrangement, as well as surface markers of both B- and T-cells 
(e.g., BCL-1, BCL-2, and CD20) (8–12). PTCLs are the most aggressive non-Hodgkin Lymphomas, 
exhibiting poor response to therapy, and poor prognosis with only 10–30% of patients having long-
term survival (10, 13).
Therefore, the need to establish a model system to study this heterogeneous lymphoma subgroup 
is warranted. We have included solely genetically manipulated mouse models, as opposed to includ-
ing xenograft models in immunocompromised mice, to study the impact of disease progression on 
the lymphoid compartment as part of the tumor microenvironmental niche. Therefore, we excluded 
models that were created without the influence of the immune response, as well as those where 
TABLe 1 | Summary of murine models of T-cell lymphomas.
Gene manipulated TS or oncogene Chr(hum) T-cell subtype affected Functional pathway % penetrance Reference
Snf5−/− TS Ch22 Mature, activated memory Self-renewal 100 (11,17, 18)
ITK–SYK Oncogene t(5;9)(q33;q22)a Mature, activated memory TCR signaling 100 (13)
Lin28b Oncogene 6q21 Mature, activated memory Let-7 miRNA signaling 100 (34)
TS, tumor suppressor; Chr, chromosome; Hum, human.
aPTCL-NOS with follicular growth is observed in human cases with this translocation.
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the B- or T-cell lymphoma were secondary to another disease 
driven by carcinogens or genetically engineered into the model. 
Similarly, this review does not include models, where PTCL-
NOS is a secondary neoplasm or a “bystander” development. 
Therefore, this review includes the compilation of these models 
and the evidence for the potential etiology of PTCL-NOS.
While disease etiology can be exceedingly difficult to discern 
since tumors arise well before patients present with symptoms, 
murine models of mature T-cell lymphomas (a disease commonly 
understudied due to prevalence) are gaining ground because of 
their twofold ability to excellently recapitulate human disease and 
to point us in the direction of which cell of origin accounts for 
the different types of neoplasms. Of the two arms of lymphocytic 
lymphomas, B-cells have received the lion’s share of research to-
date. For the largest type of mature T-cell lymphoma, peripheral 
T-cell lymphomas-not otherwise specified (PTCLs-NOS), three 
murine models really effectively model human disease. These 
models are the following: Snf5−/−, ITK–SYK fusion gene, and 
Lin28b.
Various types of animal models to recapitulate leukemias 
and lymphomas exist. The impact of such models to mimic 
lymphoproliferative diseases were reviewed previously (14). For 
this review, we conducted a literature search for murine models 
of PTCL-NOS. We conducted a literature search, a search of the 
NCI mouse database, Jackson Laboratory’s database, and MGI to 
identify all murine models for PTCL-NOS to-date. [A compre-
hensive summary of T-cell lymphoma murine models is provided 
by Warner et al. (15), and murine models of T-cell lymphoma, 
including transgenic, viral, carcinogen-induced, oncogene 
transformed, knockout, and mosaic models were last reviewed 
by Cook and Pardee (16)]. Prior reports of individual models 
capture the benefits and limitations of using mouse models to 
study lymphoma. Herein, we reviewed the models of PTCL-NOS 
in the last 15 years that mimic clinical presentation, disease sever-
ity, and genetic profiles common among patients.
Loss of Tumor Suppressor Snf5  
Leads to Aggressive PTCL
In an effort to recapitulate human PTCL, Wang et al. created in vivo 
models based on the tumor suppressor, Snf5, and determined 
the role of the TCR in tumorigenesis. SNF5 is located at 22q11 
and is deleted in 50% of T prolymphocytic leukemias, thereby 
suggesting its role as a tumor suppressor [(11, 17, 18); Table 1]. 
Specifically, a Snf5-deficient lymphoma cell line was generated 
by three sequential adoptive transfers of CD8+ splenocytes from 
Lck-Cre GFP+ Snf5fl/fl tumor-bearing mice and was transplanted 
into sublethally irradiated C57BL/6J mice. Snf5 inactivation in 
mice led to rapid onset PTCL (at ~11 weeks of age) (4, 11, 19). 
Mice with a functional TCR died at a mean age of 25  weeks, 
whereas those without a functional TCR (Rag−/−) lived past 
50 weeks without any sign of tumor (11). CD4-Cre Snf5fl/fl and 
Lck-Cre Snf5fl/fl mice developed monoclonal or oligoclonal TdT−, 
TCR+, CD3+, CD8+, CD4− mature PTCLs in spleen, liver, and 
lymph node (though not thymus – since memory, rather than 
early stage T-cells were affected) (11). CD2-Cre Snf5fl/fl mice did 
not develop tumors (11). Furthermore, CD44 serves as a marker 
of memory phenotype and self-renewal capabilities on CD8+ 
memory T cells (3, 20). CD44hi Snf5−/− cells were able to give 
rise to spontaneous tumors, whereas CD44lo were unable to do 
so. These CD44hi memory T cells were observed before tumor 
development, thereby implicating them as the potential cell of 
origin. Of total lymphoma cells in Snf5 conditional knockout 
mice, 15% expressed the CD44hi phenotype.
Most importantly, Wang et  al. aimed to determine whether 
tumorigenesis in this model was dependent upon TCR signaling 
(11). Brg1 is part of the ATP-dependent chromatin remod-
eling complex SNF/SWI and regulates the expression of CD44. 
Specifically, loss of Brg1 results in alterations in T cell develop-
ment that is nearly identical to those caused by Snf5−/−, but 
lymphoma never forms from loss of Brg1. Therefore, there is a 
strong correlation between the enrichment of memory phenotype 
in the absence of Snf5 and tumorigenesis. Consequently, to inves-
tigate tumorigenesis with TCR involvement, CD4-Cre Brg1fl/fl  
mice were used and did not give rise to CD44hi memory T cells. 
Both Myc and stem cell-like profiles are enriched with loss of Snf5 
and these are dependent upon TCR expression (11); specifically, 
Lck-Cre Snf5fl/fl Rag2−/− mice do not develop lymphoma. To that 
end, Eμ-tTA/tetO-MYC mice developed T cell lymphomas that 
can regress upon turning off Myc expression (21). Based on these 
data, tumorigenesis in a mature T-cell subtype is dependent upon 
TCR signaling (11). These data build upon other murine models 
with overexpression of the Myc transgene in hematopoietic cells 
– thus giving rise to both T-cell lymphomas and acute myeloid 
leukemias (21).
Moreover, after gene set enrichment analyses, Wang et  al. 
identified 34 differentially expressed genes unique to CD44hi 
cells that were downregulated in the non-tumorigenic CD44lo 
population. Importantly, some of these genes (ID2, CD44, and 
CTLA2A) have already been identified, as playing critical roles 
in T-cell lymphomas (22–25), though previously their ability to 
contribute to the stem cell phenotype of these cancer cells was 
unknown. Therefore, Snf5−/− oncogenesis is dependent upon 
TCR signaling. These data shed light onto the role and impact of 
the TCR in T cell lymphoma.
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iTK–SYK Fusion Kinase  
Recapitulating PTCL
In human PTCL, the recurrent translocation 5(5;9)(q33;q22) 
results in a fusion kinase ITK–SYK that is inducible by inter-
leukin-2. Additionally, 90% of PTCL cases have constitutive 
activation of SYK (26). The ITK–SYK complex associates with 
lipid rafts and triggers antigen-independent phosphorylation of 
proteins near the TCR, including CD69 (i.e., the phenotype of an 
activated T-cell) (13). SYK is part of the SYK/ZAP-70 family of 
non-receptor kinases modulating the TCR, Fc receptors on mast 
cells and macrophages, and BCR signaling (27–30). Moreover, 
SYK is present in immature T-cells and is downregulated upon 
selection of CD4+ and CD8+ cells (31–33). ITK and SYK 
are needed for APC: T cell interaction and subsequent T-cell 
activation.
Therefore, Pechloff et  al. (13) created a ITK–SYK fusion 
kinase model that recapitulates PTCL. Interestingly, this model 
essentially functions to constitutively activate antigen–receptor 
expression or “mock TCR signaling,” and thereby drive PTCL. 
This suggests that the cells involved are antigen-experienced, 
and have an activated phenotype, consistent with human cases 
and further suggesting a cell of origin, even though ITK–SYK 
expression was detected in double positive T-cells during positive 
selection in the CD4-Cre ITK–SYK model (13) (Table 1).
The phenotype of the mice bearing this fusion oncogene mim-
icked that of clinical presentation of PTCL-NOS. Specifically, 
these mice had splenomegaly with ITK–SYK expressing TCR-β+ 
T-cells with an activated phenotype (CD44+), histologically the 
splenic architecture was abnormal and infiltrated by medium- to 
large-sized lymphocytes, and had increased cellular proliferation. 
The bone marrow in all animals was affected, and metastases were 
detected in kidney, liver, and lung and these were largely mono-
clonal, as assessed by TCR-Vβ analyses via flow cytometry and 
PCR (13). Interestingly, the expansion of lymphocytes was not 
limited to CD4; rather, 61% of animals had abnormal T cells that 
were CD4+, but 23% were CD8+, and the rest were double posi-
tive (CD4+ CD8+). Such a model may recapitulate extranodal 
T-cell lymphomas, such as subcutaneous panniculitis-like T cell 
lymphomas and enteropathy-associated T-cell lymphoma, best.
Similarly, Dierks et al. (30) created a murine model of PTCL 
using transplanted cells infected with a retrovirus carrying the 
ITK–SYK fusion gene (pMSCV ITK–SYK/IRES/GFP). Bone 
marrow of sublethally irradiated Balb/c mice was infected with 
either the fusion gene-containing vector or GFP-only vector. 
PTCL was observed infiltrating LNs, BM, and skin in under a 
month, systemic inflammation, increased IL-5 and IFNgamma 
production, and tumor cells (ITK–SYK+ T cells) were resistant 
to apoptosis. Interestingly, the disease was treatable with SYK 
inhibitors (though a search of current Clinical Trials at the time 
of writing this review produced no current trials using SYK 
inhibitors against lymphoma). This model was dissimilar to 
human presentation in that it lacked Bcl6 expression and CD10 
was only in trace amounts (~10% of cells) (30). While, these mice 
did suffer from PTCL, the ability of this model to replicate human 
disease lacked in a few areas, as mentioned above. Moreover, 
these mice are laborious to maintain as compared with genetically 
engineered mice that can be bred subsequently to generate the 
phenotype in next generations.
Transgenic Mice Overexpressing Lin28b 
Develop PTCL-nOS
LIN28B, a master regulator of cellular transformation, is com-
monly upregulated in PTCL ~7.5-fold to that of control, activated 
CD4+ cells (34) and controls the let-7 family of microRNAs. 
Hematopoietic compartment-specific, Lin28b transgenic mice 
have a similar disease profile to that of human PTCL. Specifically, 
infiltration of parenchymal organs with CD4+ tumor cells, 
inflammation, increased C-reactive protein, release of inflamma-
tory cytokines, pleural effusion, and peripheral blood lymphope-
nia. The lymphopenia involved both CD4+ and CD8+ cells, with 
an expansion of tumorigenic CD4+ and CD8+ activated CD44+ 
CD62L− memory cells. These mice developed lymphoma at 
~10  months of age – significantly longer than other models 
described herein. Similarly to human PTCLs, these tumor cells 
overexpressed SYK, had decreased let-7 expression, increased 
IL-6 expression, activation of the NF-κB pathway, infiltration by 
B-cells, and lymphadenopathy (34) (Table 1).
OTHeR MODeLS OF PTCL-nOS TO 
STUDY iMPACT On CD8+ CeLLS OR 
DeveLOPMenTAL QUeSTiOnS
Other models that demonstrate T-cell proliferation, but 
at varying stages of cellular maturity, include the C3H/
He-Tg(LCKprBCL2)36Sjk/J and B6;129S1-Smarcb1tm3Sho/J mod-
els. Specifically, the C3H/He-Tg(LCKprBCL2)36Sjk/J mouse 
includes the human LCKprBCL2 transgene, which leads to an 
increased percentage of cytotoxic T cells after 10 weeks of age and 
mice show robust survival following radiation treatment or with 
treatment of an anti-CD3 monoclonal antibody (35).
Another model on the B6 and 129 background has a similar 
timeline of disease development. The B6;129S1-Smarcb1tm3Sho/J 
strain has loxP sites in opposing orientation flanking the targeted 
gene with a reversible Cre-mediated conditional null allele. When 
crossed with Mx-Cre mice, these mice develop T-cell lymphoma 
with early onset of ~11  weeks of age in 100% of mice (19). 
Furthermore, Snf5inv/− mice developed the clinical presentation 
and histology that matches mature T-cell lymphoma. Interestingly, 
complete knockout of Snf5 (or other members of the SWI/SNF 
chromatin remodeling complex) is embryonic lethal, though a 
single allele present leads to aggressive T-cell lymphoma very 
quickly (19).
Finally, the CALM/AF10 fusion gene is found in T-cell acute 
lymphoblastic leukemia and malignant lymphoma (as well as 
acute myeloid leukemia). The Vav-Cre-CALM/AF10-Tg model 
that has pan hematopoietic expression of the transgene exhibit 
lymphoma symptoms at 1  year of age, whereas no leukemia 
developed when the transgene was directed solely to CD19+ 
B-cells (36). Dutta et al. suggest that the cell of origin for CALM/
AF10+ leukemias is a stem cell or early progenitor that acquires 
additional activation mutations leading to tumorigenesis.
4Cutucache and Herek Review of Mouse Models of PTCL-NOS
Frontiers in Oncology | www.frontiersin.org September 2016 | Volume 6 | Article 206
While, these models recapitulate aggressive T-cell lymphomas 
and they have provided critical insight into T-cell biology (and 
etiology leading to PTCL), they are more helpful for studying 
developmental questions related to PTCL-NOS as compared 
with disease progression and potential treatment modalities, 
which represent the lionshare of work using murine models for 
PTCL-NOS.
SUMMARY
Often mouse xenograft models are used to mimic human disease, 
though these are poor models for T-cell lymphomas since the 
xenografts do not grow well in mice due to the lack of tumor 
microenvironment to sustain tumorigenesis. Therefore, either 
conditional knockouts or transgenic mice must be used in order 
to mimic T-cell lymphoma to study the biological consequences 
and eventually determine therapeutic applications useful for the 
disease.
While xenograft models for T-cell lymphomas have been dif-
ficult to create, Pechloff et al. and Wang et al. demonstrate that the 
cells of the models were transplantable into healthy animals with 
the original disease recapitulated. Additionally, the expansion of 
T-cells observed in all of these models was unique to malignant 
T-cells, and led to a decrease in overall healthy T-cells. These data 
suggest that the tumor cells replicate at the expense of healthy 
T cells, thereby suppressing the immune response and skewing it 
toward a more regulatory phenotype.
While all of the models described herein focused on disease 
recapitulation through manipulation of a tumor suppressor or 
oncogene, another model of aggressive T-cell lymphomas was 
created through chronic, low-dose lipopolysaccharide, and fed 
an alcohol-containing diet (37). Therefore, despite there being 
models centered around genetic mechanisms to drive T-cell 
lymphomas, it is very likely that epigenetic factors play a role as 
well. Genetically engineered mice prone to T-cell lymphoma such 
Eμ-tTA/tetO-MYC (21) and Lck-Tert (38) have also been gener-
ated (37). Although these models do not resemble the human 
disease phenotype nor affect only lymphoid cells, as the other 
models described herein do – likely because Myc and telomerase 
are critical to cellular proliferation, but have no direct association 
with the TCR or TCR-signaling partners. NOTCH and MYC 
serve as potent oncogenes in both B- and T-cell malignancies. 
Additionally, MYC modulates NOTCH and vice  versa due to 
miRNA regulation through miR-30a (39). Models with and with-
out miR-30a result in diffuse large B-cell lymphoma and T-acute 
lymphoblastic leukemia (39), thus mimicking human cases. 
Therefore, further studies will inform as to the role of miRNAs 
in PTCL-NOS.
Moreover, a recent study identified mutations in CD28 
(the TCR co-receptor) in PTCLs (40). These data, coupled 
with the role the TCR plays in T-cell lymphoma, warrant 
investigation of a conditional knockout of CD28 on PTCL 
development. The basic biology of CD28 knockout mice 
B6.129X1-Cd28tm1Jmg/Mmjax (41) includes inability to generate 
germinal centers in the spleen. Similarly, the CD28tm1Jmg mice 
show a reduction in cytokine levels and failure to proliferate in 
mixed lymphocyte culture (41).
As this review summarizes the murine models to recapitulate 
PTCL-NOS to-date, we identify useful models based on time to 
disease presentation, differing genetic manipulations to lead to 
disease, and resultant phenotypes that bear resemblance to that 
observed in humans suffering from PTCL. Moreover, a review of 
these models shed light on the potential etiology of PTCL – likely, 
this is a mature cell, either single or double positive, and it bears 
stem cell-like capabilities to regenerate, even upon passage into 
cell culture and following injection into healthy animals.
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